Articles published by Aytu BioPharma, Inc.
![](https://storage.googleapis.com/accesswire/logos/subaccounts/share/10684.png?v=0)
![](https://storage.googleapis.com/accesswire/logos/subaccounts/share/10684.png?v=0)
Aytu BioPharma Announces Initiation of the AR101 PREVEnt Trial for the Treatment of Vascular Ehlers-Danlos Syndrome
July 20, 2022
From Aytu BioPharma, Inc.
Via AccessWire
Exposures
Product Safety
Tickers
AYTU
![](https://storage.googleapis.com/accesswire/logos/subaccounts/share/10684.png?v=0)
Aytu BioPharma Announces the Appointment of Vivian Liu to the Company's Board of Directors
June 29, 2022
From Aytu BioPharma, Inc.
Via AccessWire
Tickers
AYTU
![](https://storage.googleapis.com/accesswire/logos/subaccounts/share/10684.png?v=0)
![](https://storage.googleapis.com/accesswire/logos/subaccounts/share/10684.png?v=0)
Aytu BioPharma Reports Third Quarter 2022 Financial Results and Outlines Key Strategic Priorities
May 16, 2022
From Aytu BioPharma, Inc.
Via AccessWire
Tickers
AYTU
![](https://storage.googleapis.com/accesswire/logos/subaccounts/share/10684.png?v=0)
![](https://storage.googleapis.com/accesswire/logos/subaccounts/share/10684.png?v=0)
Aytu BioPharma Announces Fast Track Designation Granted to AR101 for the Treatment of Vascular Ehlers-Danlos Syndrome
April 19, 2022
From Aytu BioPharma, Inc.
Via AccessWire
Exposures
Product Safety
Tickers
AYTU
![](https://storage.googleapis.com/accesswire/logos/subaccounts/share/10684.png?v=0)
Aytu BioPharma Announces FDA Orange Book Listing of Newly Issued Patent for Cotempla XR-ODT(R)
March 23, 2022
From Aytu BioPharma, Inc.
Via AccessWire
Topics
Intellectual Property
Tickers
AYTU
![](https://storage.googleapis.com/accesswire/logos/subaccounts/share/10684.png?v=0)
Aytu BioPharma to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit
March 22, 2022
From Aytu BioPharma, Inc.
Via AccessWire
Tickers
AYTU
![](https://storage.googleapis.com/accesswire/logos/subaccounts/share/10684.png?v=0)
![](https://storage.googleapis.com/accesswire/logos/subaccounts/share/10684.png?v=0)
![](https://storage.googleapis.com/accesswire/logos/subaccounts/share/10684.png?v=0)
![](https://storage.googleapis.com/accesswire/logos/subaccounts/share/10684.png?v=0)
![](https://storage.googleapis.com/accesswire/logos/subaccounts/share/10684.png?v=0)
Aytu BioPharma Announces Business and Pipeline Progress and Reports Second Quarter 2022 Financial Results
February 14, 2022
From Aytu BioPharma, Inc.
Via AccessWire
Tickers
AYTU
![](https://storage.googleapis.com/accesswire/logos/subaccounts/share/10684.png?v=0)
Aytu BioPharma Completes $15 Million Debt Refinancing
January 31, 2022
From Aytu BioPharma, Inc.
Via AccessWire
Tickers
AYTU
![](https://storage.googleapis.com/accesswire/logos/subaccounts/share/10684.png?v=0)
Aytu BioPharma Appoints Mark Oki as Chief Financial Officer
January 04, 2022
From Aytu BioPharma, Inc.
Via AccessWire
Tickers
AYTU
![](https://storage.googleapis.com/accesswire/logos/subaccounts/share/10684.png?v=0)
Aytu BioPharma to Present at H.C. Wainwright BioConnect Conference
January 03, 2022
From Aytu BioPharma, Inc.
Via AccessWire
Tickers
AYTU
![](https://storage.googleapis.com/accesswire/logos/subaccounts/share/10684.png?v=0)
![](https://storage.googleapis.com/accesswire/logos/subaccounts/share/10684.png?v=0)
Aytu BioPharma Receives Orphan Drug Designation from FDA for AR101 for Treatment of Vascular Ehlers-Danlos Syndrome
December 08, 2021
From Aytu BioPharma, Inc.
Via AccessWire
Topics
Regulatory Compliance
Tickers
AYTU
![](https://storage.googleapis.com/accesswire/logos/subaccounts/share/10684.png?v=0)
Aytu BioPharma Announces Issuance of First U.S. Patent Supporting Healight Ultraviolet-A Respiratory Catheter
November 23, 2021
From Aytu BioPharma, Inc.
Via AccessWire
Tickers
AYTU
![](https://storage.googleapis.com/accesswire/logos/subaccounts/share/10684.png?v=0)
Aytu BioPharma Ranked Number 178 Fastest-Growing Company in North America on the 2021 Deloitte Technology Fast 50(TM)
November 17, 2021
From Aytu BioPharma, Inc.
Via AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Tickers
AYTU
![](https://storage.googleapis.com/accesswire/logos/subaccounts/share/10684.png?v=0)
Aytu BioPharma Reports First Quarter 2022 Financial Results
November 15, 2021
From Aytu BioPharma, Inc.
Via AccessWire
Topics
Regulatory Compliance
Tickers
AYTU
![](https://storage.googleapis.com/accesswire/logos/subaccounts/share/10684.png?v=0)
Aytu BioPharma to Report First Quarter Fiscal 2022 Results and Provide Business Update on November 15, 2021
November 08, 2021
From Aytu BioPharma, Inc.
Via AccessWire
Tickers
AYTU
![](https://storage.googleapis.com/accesswire/logos/subaccounts/share/10684.png)
![](https://storage.googleapis.com/accesswire/logos/subaccounts/share/10684.png)
Aytu BioPharma Reports Fourth Quarter and Full-Year Fiscal 2021 Financial Results
September 27, 2021
From Aytu BioPharma, Inc.
Via AccessWire
Topics
Regulatory Compliance
Tickers
AYTU
![](https://storage.googleapis.com/accesswire/logos/subaccounts/share/10684.png)
![](https://storage.googleapis.com/accesswire/logos/subaccounts/share/10684.png)
![](https://storage.googleapis.com/accesswire/logos/subaccounts/share/10684.png)
Aytu BioPharma to Present at Upcoming September Investor Conferences
September 07, 2021
From Aytu BioPharma, Inc.
Via AccessWire
Tickers
AYTU
![](https://storage.googleapis.com/accesswire/logos/subaccounts/share/10684.png)
![](https://storage.googleapis.com/accesswire/logos/subaccounts/share/10684.png)
Aytu BioPharma Announces Peer-Reviewed Publication of Clinical Results from Healight(TM) Pilot Study
June 28, 2021
From Aytu BioPharma, Inc.
Via AccessWire
Topics
Regulatory Compliance
Tickers
AYTU
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.